ru-66647 has been researched along with Cross-Infection* in 2 studies
1 review(s) available for ru-66647 and Cross-Infection
Article | Year |
---|---|
New antibiotic agents: problems and prospects.
Surgical site infections are the third most common healthcare-associated infection, often leading to prolonged hospital stay and excessive expenditures. Management of these infections has become more challenging due to rising rates of multi-drug-resistant organisms and few new antibiotic options.. This paper reviews the literature, summarizes the epidemiology of surgical site infections and the threat of antibiotic-resistant bacteria, and provides an insight into new treatment options for this condition.. Patients with surgical site infections are at greater risk of acquiring healthcare-associated antibiotic-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) sp., and extended-spectrum beta-lactamase-(ESBL)-producing Escherichia coli and Klebsiella pneumoniae. Multi-drug-resistant Pseudomonas aeruginosa and Bacteroides fragilis are also a growing problem. Several useful drugs have recently become available for the management of serious, gram-positive infections (e.g., daptomycin, linezolid, telithromycin). Tigecycline, the first-in-class glycylcycline, has broad-spectrum in vitro activity, including against MRSA, VRE, resistant enteric gram-negative bacilli (e.g., Acinetobacter sp.), "atypical" pathogens, and anaerobes. Phase 3 clinical trials suggest that tigecycline will be an excellent option for antibiotic monotherapy for complicated skin and soft tissue infections (cSSSI) and intra-abdominal infections. Oritavancin and dalbavacin, two novel glycopeptide antibiotics that are also in late-stage clinical development, appear that they, too, will be useful for cSSSI due to resistant, gram-positive bacteria.. Multi-drug-resistant pathogens are threatening the success of available antibiotic therapy. Many new options are useful for infections due to multi-drug-resistant, gram-positive bacteria. Tigecycline is a promising new agent that provides coverage against a broad spectrum of gram-positive and gram-negative, aerobic, facultative, and anaerobic strains, including resistant isolates, and may make broad-spectrum, single-agent therapy possible. Topics: Acetamides; Acinetobacter; Anti-Bacterial Agents; Cross Infection; Daptomycin; Drug Resistance, Multiple, Bacterial; Humans; Ketolides; Linezolid; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Pseudomonas aeruginosa; Surgical Wound Infection; Tigecycline; Vancomycin Resistance | 2005 |
1 other study(ies) available for ru-66647 and Cross-Infection
Article | Year |
---|---|
Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.
The rates of resistance to erythromycin and clindamycin among Streptococcus agalactiae strains isolated in our hospital increased from 4.2 and 0.8% in 1993 to 17.4 and 12.1%, respectively, in 2001. Erythromycin resistance was mainly due to the presence of an Erm(B) methylase, while the M phenotype was detected in 3.8% of the strains. Telithromycin was very active against erythromycin-resistant strains, irrespective of their mechanisms of macrolide resistance. Topics: Anti-Bacterial Agents; Clindamycin; Cross Infection; Drug Resistance, Bacterial; Erythromycin; Humans; Infant, Newborn; Ketolides; Macrolides; Microbial Sensitivity Tests; Spain; Streptococcal Infections; Streptococcus agalactiae; Tetracycline Resistance | 2003 |